New CEO Mattessich Brings in New Skills, Leadership to Help Ocular Therapeutix Reach Potential
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 172″]
New CEO Antony Mattessich says Ocular Therapeutix has learned its mistakes after receiving two CRLs from the FDA. With new leadership and a clear vision, the company is ready to push forward as a full-fledged biopharmaceutical company.